These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 15272581)

  • 1. [Molecular-target drug].
    Sone S; Yano S; Nishioka Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1034-40. PubMed ID: 15272581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular targeted therapy for cancer].
    Sone S; Kuramoto T; Sato S; Mitsuhashi A; Kakiuchi S; Goto H; Tada H; Nishioka Y
    Nihon Rinsho; 2010 Jun; 68(6):997-1006. PubMed ID: 20535947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics. Pediatric drugs, biomarkers and new therapies.
    Kibble A
    IDrugs; 2007 Jan; 10(1):5-7. PubMed ID: 17187303
    [No Abstract]   [Full Text] [Related]  

  • 7. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microtubule-targeting agents in angiogenesis: where do we stand?
    Pasquier E; Honoré S; Braguer D
    Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumorigenic effects of cannabinoids beyond apoptosis.
    Freimuth N; Ramer R; Hinz B
    J Pharmacol Exp Ther; 2010 Feb; 332(2):336-44. PubMed ID: 19889794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in clinical oncoproteomics.
    Jain KK
    J BUON; 2007 Sep; 12 Suppl 1():S31-8. PubMed ID: 17935275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Problems of tumor progression: doubts or hopes at the turn of the Millennium?].
    Tímár J
    Orv Hetil; 2000 Apr; 141(17):891-9. PubMed ID: 10827469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular insights into cancer invasion: strategies for prevention and intervention.
    Kohn EC; Liotta LA
    Cancer Res; 1995 May; 55(9):1856-62. PubMed ID: 7728753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins.
    Kunnumakkara AB; Anand P; Aggarwal BB
    Cancer Lett; 2008 Oct; 269(2):199-225. PubMed ID: 18479807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting angiogenesis with integrative cancer therapies.
    Yance DR; Sagar SM
    Integr Cancer Ther; 2006 Mar; 5(1):9-29. PubMed ID: 16484711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical endpoints for drug development in prostate cancer.
    Ramiah V; George DJ; Armstrong AJ
    Curr Opin Urol; 2008 May; 18(3):303-8. PubMed ID: 18382240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and cellular biomarkers for angiogenesis in clinical oncology.
    Bertolini F; Mancuso P; Shaked Y; Kerbel RS
    Drug Discov Today; 2007 Oct; 12(19-20):806-12. PubMed ID: 17933680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
    Loges S; Mazzone M; Hohensinner P; Carmeliet P
    Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.